Last mentioned: Mar 18, 2026
Expansion Target
Goal to reach 130 active sales territories by fiscal year-end
Earnings Release
Announced 63% revenue growth and VA hospital network access
Q3 Fiscal End
Closed third quarter with 100 active sales territories
Equity Offering
Completed capital raise to bolster cash position to $291M
Kestra Medical (KMTS) delivered a strong Q3 2026 performance, highlighted by a 63% year-over-year revenue increase and the ninth consecutive quarter of gross margin expansion. While net losses widened to $34.2 million due to aggressive sales force expansion, the company secured critical access to the VA Federal Supply Schedule and expanded its Florida Medicaid footprint.
Kestra Medical reported a 63% year-over-year revenue increase to $24.6 million in Q3 2026, driven by record prescriptions for its Assure wearable cardioverter defibrillator. The company significantly expanded its market access through a new U.S. Department of Veterans Affairs contract and improved Medicaid coverage in Florida.
Kestra Medical (KMTS) delivered a robust Q3 2026 with $24.6 million in revenue, driven by a 58% surge in Assure system prescriptions. Despite a widening net loss of $34.2 million, the company secured critical access to the VA Federal Supply Schedule and expanded its Florida Medicaid footprint.